Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: progestin therapy Clear all
Completed Phase 4 Interventional Results available

Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids

NCT03317795
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Menorrhagia, Uterine Fibroids
Interventions
Levonorgestrel IUS, Tranexamic Acid
Drug
Lead sponsor
Shannon K. Laughlin-Tommaso
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Norgestrel 75 mcg on Cervical Mucus and Ovarian Activity During Perfect Use, After One Delayed Intake and After a Missed Pill

NCT03585712
View directory record Official record
Conditions
Contraception
Interventions
Norgestrel 0.075 mg
Drug
Lead sponsor
HRA Pharma
Industry
Eligibility
18 Years to 35 Years · Female only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
2
States / cities
Sacramento, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Oral Estradiol and Progesterone Therapy on Vaginal Cytokines in Postmenopausal Women

NCT02224313
View directory record Official record
Conditions
Menopause
Interventions
oral estradiol 1.0 mg, oral progesterone 100 mg
Drug
Lead sponsor
Intira Sriprasert
Other
Eligibility
20 Years to 65 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

Bay98-7196, Dose Finding / POC Study

NCT02203331
View directory record Official record
Conditions
Endometriosis
Interventions
Placebo, Levonorgestrel, Anastrozole, Lupron / Leuprolide acetate
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Female only
Enrollment
319 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
25
States / cities
San Diego, California • San Francisco, California • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2023 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Not applicable Interventional Results available

Improving the Clinical Encounter to Enhance Delivery of an Individualized Prematurity Prevention Plan

NCT04149002
View directory record Official record
Conditions
Preterm Birth
Interventions
Intervention Arm Weekly IP3 text messages, Active Control Arm General pregnancy text messages
Behavioral · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 2, 2022 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Safety and Efficacy of a Contraceptive Vaginal Ring Delivering Nestorone® and Ethinyl Estradiol

NCT00263341
View directory record Official record
Conditions
Contraception
Interventions
NES/EE CVR
Combination Product
Lead sponsor
Population Council
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
1,135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2014
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 23, 2026, 9:06 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Uterine Electrical Activity Before and After Progesterone Treatment for Preterm Labor

NCT01406197
View directory record Official record
Conditions
Preterm Labor
Interventions
Experimental: Vaginal progesterone, Experimental: Topical progesterone, Experimental: Intramuscular progesterone
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
17 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Oct 23, 2026, 9:06 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Hormone Replacement for Premature Ovarian Insufficiency

NCT02922348
View directory record Official record
Conditions
Primary Ovarian Insufficiency
Interventions
Hormone Replacement Therapy, Combined Oral Contraceptives
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
14 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 23, 2026, 9:06 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Estrogen and Microvascular Function

NCT06043310
View directory record Official record
Conditions
Estrogen, Cardiovascular Diseases, Microvasculature, Oral Contraceptive Use
Interventions
Nω-nitro-L-arginine methyl ester (L-NAME), Acetylcholine, Sodium Nitroprusside
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2031
U.S. locations
1
States / cities
Wauwatosa, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 23, 2026, 9:06 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis

NCT00000430
View directory record Official record
Conditions
Osteopenia, Osteoporosis
Interventions
Alendronate, Estrogen/progestin therapy
Drug
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
60 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2004
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 4, 2007 · Synced Oct 23, 2026, 9:06 AM EDT
Not listed Phase 2 Interventional

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

NCT01466114
View directory record Official record
Conditions
Relapsing-remitting Multiple Sclerosis, Secondary-progressive Multiple Sclerosis, Primary-progressive Multiple Sclerosis
Interventions
estriol, Placebo, Norethindrone, Progestin Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Albuquerque, New Mexico + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 2 Interventional Results available

A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)

NCT00451204
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
Estriol, Placebo, Copaxone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
15
States / cities
Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 23, 2026, 9:06 AM EDT
Withdrawn Phase 2 Interventional

SIRT-1 Antagonism for Endometrial Receptivity

NCT04184323
View directory record Official record
Conditions
Endometriosis, Uterine Diseases, Endometrial Diseases, Infertility Unexplained, Infertility; Female, Nonimplantation
Interventions
EX-527 (Selisistat), Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 17, 2021 · Synced Oct 23, 2026, 9:06 AM EDT
Active, not recruiting No phase listed Observational

An Observational Study to Learn How Mirena and Other Progestogen Treatments Are Used for Endometrial Protection in Women 40+ With a Uterus in the United States Receiving Estrogen Therapy, and Their Respective Health Outcomes

NCT07795606
View directory record Official record
Conditions
Estrogen Therapy
Interventions
Estrogen therapy, Mirena levonorgestrel-releasing intrauterine system, Other progestogen therapy
Drug · Device
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older · Female only
Enrollment
456,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Ann Arbor, Michigan • Eden Prairie, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 9:06 AM EDT
Terminated No phase listed Observational

17-OHPC in Pregnancy: IM vs SC Routes

NCT04183452
View directory record Official record
Conditions
Preterm Birth
Interventions
17-Hydroxyprogesterone Caproate 250 mg IM Dose, 17-Hydroxyprogesterone Caproate 275 mg SC Dose
Drug
Lead sponsor
Steve N. Caritis, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
4
States / cities
Newark, Delaware • Durham, North Carolina • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2023 · Synced Oct 23, 2026, 9:06 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Impact of Progestin-only Contraception on Bleeding Patterns in Individuals Initiating GATT

NCT06230770
View directory record Official record
Conditions
Gender, Contraception
Interventions
Bleeding data
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 23, 2026, 9:06 AM EDT
Terminated Phase 2 Interventional Results available

Preservation of Ovarian Function After Hematopoietic Cell Transplant

NCT01343368
View directory record Official record
Conditions
Multiple Myeloma, Non-Hodgkin Lymphoma, Hodgkin Disease, Acute Myeloid Leukemia, Myeloproliferative Disorders
Interventions
Leuprolide, hematopoietic cell transplant, reduced intensity allogeneic HCT
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
50 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Progesterone Treatment for Cocaine-dependent Women: A Pilot Study

NCT00632099
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Oral micronized progesterone, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 23, 2026, 9:06 AM EDT
Recruiting Phase 2 Interventional

Progestins for the Treatment of Endometrial Cancer or Precancers of the Uterus Before Surgery, The Pro-Window Trial

NCT07436793
View directory record Official record
Conditions
Endometrial Endometrioid Adenocarcinoma, Endometrial Hyperplasia
Interventions
Biopsy Procedure, Curettage Procedure, Hysterectomy, Megestrol Acetate, Progesterone Only Hormone Replacement Therapy
Procedure · Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
4
States / cities
Iowa City, Iowa • Albuquerque, New Mexico • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 2 Interventional

Progesterone Treatment in Female Smokers - 12

NCT00000295
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Micronized Progesterone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 23, 2026, 9:06 AM EDT
Not listed Phase 2 Interventional

Virexxa (Sodium Cridanimod) w/Progestin Therapy in Pts w/Progesterone Receptor Neg Recurrent/Persistent Endometrial CA

NCT02064725
View directory record Official record
Conditions
Recurrent or Persistent Endometrial Carcinoma
Interventions
Sodium cridanimod
Drug
Lead sponsor
Kevelt AS
Industry
Eligibility
18 Years and older · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
4
States / cities
San Jose, California • Santa Rosa, California • Detroit, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 23, 2026, 9:06 AM EDT
Terminated Not applicable Interventional Results available

Progestin-induced Endometrial Shedding in PCOS (The PIES in PCOS Study)

NCT01718444
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Infertility
Interventions
Progestin, Clomiphene Citrate
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 29, 2020 · Synced Oct 23, 2026, 9:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

NES Gel-1, To Evaluate Nestorone Gel in Combination With Testosterone Gel

NCT00229593
View directory record Official record
Conditions
Contraception
Interventions
Nestorone gel, Testosterone Gel
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
2
States / cities
Torrance, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 23, 2026, 9:06 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Blocking Mifepristone Action With Progesterone

NCT03774745
View directory record Official record
Conditions
Pregnancy, Unwanted
Interventions
Mifepristone 200 MG, micronized Progesterone, Placebo oral capsule
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
3
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 23, 2026, 9:06 AM EDT